Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Org.nummer: 925400262
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2017.11.22, US 201762589822 P
2018.06.29, US 201862691709 P
ANDERSON: "Practical Process Research & Development", 1 January 2000, ACADEMIC PRESS, San Diego, ISBN: 978-0-12-059475-7, article "Chapter 11, Tools for Purifying the Product: Column Chromatography, Crystallization and Reslurrying", pages: 223 - 224, XP002565895 (B1)
Aungst: "Optimising Oral Bioavailability of Pharmaceutical Leads" Drug Development, 2006, 84-86. (B1)
BERGE ET AL.: "PHARMACEUTICALS SALTS", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1 January 1977 (1977-01-01), pages 1 - 19, XP000562636, ISSN: 0022-3549, DOI: 10.1002/JPS.2600660104 (B1)
BYRN ET AL.: "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, 1 January 1995 (1995-01-01), pages 945 - 954, XP055531015, DOI: 10.1023/A:1016241927429 (B1)
CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022 (B1)
DATABASE IMSRESEARCH [online] IQVIA, LONDON, UK; 13 December 2018 (2018-12-13), XP002788334, Database accession no. 2014:8 (B1)
WO-A1-2016/201227 (B1)
Fink et al.: "Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic Modelling", Clinical Pharmacology & Therapeutics 2020, 107, 650-661. (B1)
HANCOCK; ZOGRAFI: "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 86, no. 1, 1 January 1997 (1997-01-01), pages 1 - 12, XP055274556, DOI: 10.1021/js9601896 (B1)
HARWOOD; MOODY: "Experimental organic chemistry - Principles and practice", 1 January 1989, BLACKWELL SCIENCE, ISBN: 978-0-632-02016-4, pages: 127 - 132, XP003025361 (B1)
STAHL ET AL.: "Pharmaceutical Salts: Properties, Selections, and Use, passages", 1 January 2002, HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, ZÜRICH : VERL. HELVETICA CHIMICA ACTA ; WEINHEIM [U.A.] : WILEY-VCH, DE, PAGE(S) 212-214,254,305, ISBN: 978-3-906390-26-0, pages: 212-214, 254, 305 - 306, XP002550486 (B1)
US-B2- 8 785 450 (B1)
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 5 December 2017 (2017-12-05), XP002788333, Database accession no. 2151847-10-6 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3713919)
|
Utgående
EP Registreringsbrev (3210) (PTEP3713919)
|
Innkommende, AR570896027
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 7. avg. år (EP) | 2024.11.29 | 2860 | COMPUTER PACKAGES INC. | Betalt og godkjent |
Årsavgift 6. avg. år (EP) | 2023.11.29 | 2000 | COMPUTER PACKAGES INC. | Betalt og godkjent |
32311804 expand_more expand_less | 2023.10.11 | 5500 | AWA NORWAY AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|